LBRX - Total Utang marang Modal LB Corp

The biopharmaceutical business of LB Pharmaceuticals Inc (LBRX) relies on a steady demand for psychotropic agents, although geopolitical tensions could disrupt logistics and patent protection. This chart illustrating price changes captures a debt-to-equity ratio of 0.02, while funds are being spent as planned on medical tests without a liquidity deficit. LB Pharmaceuticals Inc (LBRX) minimizes risks by developing innovative therapies for severe CNS lesions.

LBRX: Total Utang marang Modal LB Pharmaceuticals 12.09.2025 - 29.10.2026

Rincian analitis perusahaan LB Pharmaceuticals Inc

- rega lan prakiraan konsensus rega:

Bagan rega LB Pharmaceuticals|LBRX - Bagan tingkat prakiraan

- statistik kapitalisasi pasar:

Kapitalisasi pasar LB Pharmaceuticals|LBRX - Nilai Dipunlarasaken Utang lan Kas

- indikator kapitalisasi buku:

Nilai Buku saben Saham LB Pharmaceuticals|LBRX - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku lbpharma.us|LBRX - Nilai Agregat Aset

- indikator total utang lan likuiditas perusahaan:

Utang marang Ekuitas LB Pharmaceuticals Inc|LBRX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal LB Pharmaceuticals Inc|LBRX - Gunggung utang perusahaan|Utang marang nilai buku LB Pharmaceuticals|LBRX - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan LB Pharmaceuticals

Analisis dhasar perusahaan:LB Pharmaceuticals

Financial stability during the R&D phase is critical for LB Pharmaceuticals Inc (LBRX), a venture developer of schizophrenia medications. This indicator measures the proportion of borrowed funds relative to equity, determining the business's degree of dependence on creditors. Analyzing the balance between debt and equity allows for an assessment of default risk in the absence of revenue. The trend of this metric reflects the company's ability to fund innovation without excessive debt load. Low leverage confirms a margin of safety before entering the commercialization stage.

Analisis pesaing LB Pharmaceuticals Inc

Utang marang Ekuitas Alkermes|Avadel Pharmaceuticals PLC - Utang Agregat marang Ekuitas|Total Utang marang Modal ATAI|GHRS (GH Research Group) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal MNMD (Mind Medicine)|Total Utang marang Modal compasspathways.com CMPS|DRUG - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi VNDA (Vanda Pharma)|cybin.com (CYBN) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Alto Neuroscience Corp|NRXP (NRx Pharmaceuticals) - Total Utang marang Modal|Total Utang marang Modal Cingulate Corp|Rasio Total Utang marang Ekuitas SILO (Silo Pharma, Inc.)|CPHI (chinapharmaholdings.com) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas Clearmind Medicine CMND|PBM (Psyence Bio) - Utang Agregat marang Ekuitas|SPRC - Utang marang Ekuitas|Koefisien Total Utang marang Modal seelostherapeutics.com SEEL|VRPX (virpaxpharma.com) - Rasio Total Utang marang Ekuitas|Utang marang Modal Karuna Therapeutics Inc (KRTX)